# BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct07628985` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07628985](<https://clinicaltrials.gov/study/NCT07628985>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07628985

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 374 participants.

## Technical summary

Registry record NCT07628985. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 374 participants (planned count; ClinicalTrials.gov record NCT07628985, source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)
- Planned start: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07628985, source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07628985, source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07628985, source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT07628985, source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07628985-2026-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Biological): Bofanglutide
- Intervention (Biological): Semaglutide
- Lead sponsor: Carnot Laboratories
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)

## Provenance

Content hash: 3db9bc388f2c9c3d6003a5d0c094c6f4fa606347949d75d50974c16c7d2ebfe3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
